The murine Leishmania major model has proven fertile ground for the elucidation of CD4+ T cell effector subset differentiation in vivo. The availability of a highly susceptible inbred strain, BALB/c, that develops progressive disease due to the aberrant differentiation of Th2, as opposed to protective Th1, responses, has allowed the identification of both T cell intrinsic as well as T cell extrinsic properties that combine to mediate disease outcome. The intrinsic T cell phenotype relates to the capacity of BALB/c-derived CD4+ T cells to acquire the potential to secrete IL-4 more readily than cells from other strains of mice. The extrinsic T cell phenotype relates to the creation of a T cell repertoire capable of recognizing the immunodominant parasite antigen. Together, the two traits confer the aberrant response seen in susceptible mice challenged with L. major.

Download full-text PDF

Source

Publication Analysis

Top Keywords

murine leishmania
8
leishmania major
8
major model
8
cell phenotype
8
phenotype relates
8
cell
6
disease susceptibility
4
susceptibility development
4
development cytokine
4
cytokine repertoire
4

Similar Publications

In vitro and in vivo leishmanicidal and trypanocidal activities of isoflavans from Tabebuia chrysantha (Jacq.) G. Nicholson timber by-products.

Exp Parasitol

January 2025

Grupo de Química Orgánica de Productos Naturales, Instituto de Química, Universidad de Antioquia-UdeA. Calle 70 # 52-21, Medellín, Colombia. Electronic address:

Cutaneous Leishmaniasis and Chagas disease are neglected tropical diseases that affect millions worldwide. Despite the high morbidity associated with these infections, current treatments are often highly toxic and are showing diminishing efficacy. Thus, new therapeutic options are urgently needed.

View Article and Find Full Text PDF

Thiadiazine thione (THTT) has gained significant interest owing to its pharmacological potentials, particularly its antiparasitic and anti-inflammatory properties. Leishmaniasis is a clinical syndrome caused by infection with species and is associated with an inflammatory response and nociception. The available treatments against leishmaniasis are inadequate, as they are associated with high cost, toxicity, and increased resistance.

View Article and Find Full Text PDF

One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), isolated from the red alga , in a pharmaceutical form supported on Sepigel, and the in vivo efficacy against a mouse model of cutaneous leishmaniasis. Studying the ultrastructural effect of DT was also carried out to verify the suspected damage at the cellular level and determine the severity of damages produced in the homeostasis of promastigotes.

View Article and Find Full Text PDF

Pretreatment with serine protease inhibitors impairs Leishmania amazonensis survival on macrophages.

Parasit Vectors

January 2025

Laboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, 21040-360, Brazil.

Background: Leishmaniases are neglected tropical diseases with great clinical and epidemiological importance. The current chemotherapy available for the treatment of leishmaniasis presents several problems, such as adverse effects, toxicity, long treatment time, and parasite resistance. The discovery of new therapeutic alternatives is extremely essential, and the discovery of cellular targets is a tool that helps in the development of new drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!